Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

Pulmonology, an esteemed journal published by Elsevier, serves as a vital platform for advancing knowledge in the field of Pulmonary and Respiratory Medicine. Since its transition to Open Access in 2018, this journal has successfully fostered a global readership, allowing for unrestricted dissemination of cutting-edge research. With an impressive Scopus ranking of #8 out of 155 in its category and a notable 2023 Q1 status, Pulmonology consistently showcases high-quality studies and reviews that contribute to the understanding and treatment of respiratory disorders. Authors and readers alike benefit from its commitment to publish influential research that addresses contemporary challenges in lung health. By bridging the gap between theory and clinical practice, the journal paves the way for innovative practices in pulmonology, making it an indispensable resource for researchers, healthcare professionals, and students interested in this dynamic field.

Respiratory Medicine is a leading journal in the field of pulmonary and respiratory medicine, dedicated to advancing knowledge and research from 1989 to 2024. Published by W B Saunders Co Ltd, this esteemed journal is recognized for its high impact, reflected in its Q1 quartile ranking in 2023 within the category of Pulmonary and Respiratory Medicine and its impressive Scopus ranking of 27 out of 155 journals, placing it in the 82nd percentile. With a focus on publishing groundbreaking research, comprehensive reviews, and innovative practices, Respiratory Medicine serves as an essential resource for health professionals, researchers, and students aiming to improve patient outcomes and understand complex respiratory conditions. While the journal is not Open Access, its contributions to the scientific community are invaluable, providing insights that drive both academic and clinical advancements in respiratory health.

Welcome to the Journal of Thoracic Disease, a premier scholarly journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by AME PUBLISHING COMPANY in Hong Kong, this journal has established itself as a critical platform for the dissemination of innovative research and clinical advancements since its inception in 2009. With an impressive Q2 ranking in the Scopus category of Pulmonary and Respiratory Medicine, it is recognized for its contribution to the academic community, featuring a broad range of original research, reviews, and case studies that address contemporary challenges in thoracic disease management. The journal is committed to Open Access principles, ensuring that high-quality research is readily available to a global audience, further enhancing its impact factor and reach. Researchers, healthcare professionals, and students alike will find invaluable insights within its pages, making Journal of Thoracic Disease an essential resource for those invested in the respiratory health domain.

The EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.

THORACIC AND CARDIOVASCULAR SURGEON, published by GEORG THIEME VERLAG KG, is a prestigious journal dedicated to the fields of cardiology, cardiovascular surgery, and pulmonary medicine. Since its inception in 1973, the journal has served as a vital platform for disseminating cutting-edge research and innovative techniques, contributing significantly to advancements in patient care and surgical practices. With an emerging recognition evidenced by its category quartiles, ranking Q3 in Cardiology and Cardiovascular Medicine and Q2 in Surgery as of 2023, it positions itself as an essential resource for both clinicians and researchers alike. Although this journal does not currently offer Open Access options, it maintains a strong impact with Scopus rankings that highlight its relevance within the medicine and surgery disciplines. The journal is particularly committed to bridging the gap between theoretical research and practical application, making it crucial for professionals aiming to stay informed on the latest developments in thoracic and cardiovascular health. Join a community of scholars dedicated to excellence in these critical areas of medicine.

Minerva Respiratory Medicine is a prominent academic journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by EDIZIONI MINERVA MEDICA in Italy, this journal provides a vital platform for the dissemination of innovative research, clinical studies, and review articles that address the complexities of respiratory health. With an ISSN of 2784-8477 and an E-ISSN of 2724-6493, it serves as an open-access resource, allowing researchers, healthcare professionals, and students access to invaluable information without barriers. The journal is categorized in the fourth quartile of the 2023 rankings in the field of pulmonary and respiratory medicine, indicating its emerging role in the academic landscape. Despite its nascent status—converging from 2021 to 2024—Minerva Respiratory Medicine is committed to enhancing knowledge and practice in respiratory care, focusing on both innovative therapies and traditional approaches. With its aim to foster collaboration and communication among professionals in the field, this journal is an essential resource for those passionate about improving respiratory health outcomes.

Pulmonary Medicine, published by HINDAWI LTD, stands as a prestigious open-access journal since 2010, dedicated to advancing the field of pulmonary and respiratory medicine. Located in Egypt, this journal is indexed with an ISSN of 2090-1836 and an E-ISSN of 2090-1844, and it has attained a commendable Q2 ranking in both the miscellaneous medicine and pulmonary health categories, indicative of its significant impact and quality. With an impressive Scopus ranking of #15 out of 155 in the pulmonary and respiratory medicine category, the journal is positioned in the 90th percentile, highlighting its relevance and contribution to ongoing research. The journal aims to publish high-quality original research, reviews, and clinical studies that address pressing issues in pulmonary health, making it a vital resource for researchers, clinicians, and students seeking to enhance their understanding and practice in respiratory medicine. By embracing an open-access model, Pulmonary Medicine provides a platform for disseminating knowledge, fostering collaboration, and driving innovation within the global scientific community.

Chronic Respiratory Disease is a leading peer-reviewed journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by SAGE Publications Ltd since its inception in 2004, this open-access journal has been at the forefront of disseminating high-quality research aimed at addressing chronic respiratory conditions. With an impressive impact factor and classified as Q1 in the 2023 category of Pulmonary and Respiratory Medicine, it ranks an admirable #45 out of 155 in Scopus, placing it in the 71st percentile of its field. This journal features a diverse range of studies, reviews, and clinical insights that cater to researchers, healthcare professionals, and students alike, encouraging the exchange of innovative ideas and practices in respiratory disease management. Operating out of London, UK, Chronic Respiratory Disease exemplifies a commitment to openness, having transitioned to open access since 2017, thereby ensuring that pivotal research is readily accessible to a global audience engaged in the improvement of respiratory health.

Lung India is a premier open-access journal dedicated to the dissemination of high-quality research in the field of Pulmonary and Respiratory Medicine. Published by Wolters Kluwer Medknow Publications, it has been forging a path in respiratory healthcare since its inception in 2004. With its impactful contributions to clinical practice and research, Lung India holds a solid position in the academic landscape, evidenced by its ranking in the Q3 quartile for Pulmonary and Respiratory Medicine as of 2023, and its Scopus rank of #99 out of 155. The journal is particularly important for researchers, clinicians, and students in India and beyond, providing a platform for the latest findings and developments in respiratory care, lung disease management, and innovative treatment methods. With a commitment to accessibility, Lung India aims to promote knowledge sharing among professionals and support the advancement of respiratory health. The journal is well-equipped to cater to a diverse audience, ensuring that vital research is readily accessible and impactful.